ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.
Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of innovative, first-in-class medical radioisotopes and generator platforms for a new generation of targeted cancer diagnostics and therapies.
Furthermore, ITM is developing a proprietary portfolio and growing Precision Oncology Pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, prostate cancer, folate receptor α positive tumors like ovarian cancer or NSCL adenocarcinoma, as well as osteosarcoma and bone metastases. ITM’s lead candidate n.c.a. 177Lu-edotreotide, a Targeted Radionuclide Therapy to specifically target neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs), is currently undergoing two international pivotal phase III clinical trials, COMPETE and COMPOSE.
ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.
